Rosuvastatin is prohibited for pregnant women and lactating women. Women who are at risk of being pregnant should use appropriate contraception. Because cholesterol and other cholesterol biosynthesis products are important for embryonic development, the risk from
HMG-CoA reductase inhibition outweighs the benefit of treatment for pregnant women. Animal studies provide limited evidence of reproductive toxicity. If the patient is pregnant during the use of Rosuvastatin, treatment should be discontinued immediately. Rosuvastatin can be secreted into rat breast milk. There is no data on Rosuvastatin secretion into human breast.